Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 14/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480923 | 1.00 | CCR5 (0.48) | CCR5KDM4DKCNA3CKS1BSKP1 | |
| SCHEMBL19627679 | 0.84 | KCNA3 (0.51) | CCR5KDM4DKCNA3CKS1BSKP1 | |
| SCHEMBL19627682 | 0.84 | KCNA3 (0.51) | CCR5KDM4DKCNA3CKS1BSKP1 | |
| SCHEMBL19627621 | 0.82 | KDM4D (0.52) | CCR5KDM4DKCNA3CTSK | |
| SCHEMBL19627623 | 0.82 | KDM4D (0.52) | CCR5KDM4DKCNA3CTSK | |
| SCHEMBL14127113 | 0.81 | KCNA3 (0.52) | CCR5KDM4DKCNA3CKS1BSKP1 | |
| SCHEMBL20488646 | 0.79 | KMT2A (0.43) | CCR5KCNA3CKS1BSKP1SKP2 | |
| SCHEMBL13356554 | 0.78 | DRD4 (0.57) | CCR5KDM4DKCNA3CKS1BSKP1 | |
| SCHEMBL26891505 | 0.77 | ALDH1A1 (0.50) | KMT2A | |
| SCHEMBL6080372 | 0.77 | CCR5 (0.56) | CCR5KDM4DKCNA3CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-19 | — | — | US | disclosed |
| CN-110573499-A | inhibitors of α v β 6 integrin | 莫菲克医疗股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018160521-A2 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CCR5 457/4885KDM4D 3517/4885KCNA3 900/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CCR5 457/4885KDM4D 3517/4885KCNA3 900/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | CCR5 662/4885KDM4D 3874/4885KCNA3 1212/4885 |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGAV, ITGA6 | CCR5 757/4885KDM4D 2479/4885KCNA3 514/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CCR5 505/4885KDM4D 3525/4885KCNA3 893/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CCR5 457/4885KDM4D 3517/4885KCNA3 900/4885 |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CCR5 457/4885KDM4D 3517/4885KCNA3 900/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | CCR5 457/4885KDM4D 3517/4885KCNA3 900/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CCR5 505/4885KDM4D 3525/4885KCNA3 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.